h. pylori vaccine - Cancer Science

What is H. pylori?

H. pylori is a type of bacteria that infects the stomach lining and is a major cause of ulcers. It is estimated that about half of the world's population is infected with H. pylori, often without any symptoms.

How is H. pylori related to Cancer?

H. pylori infection has been strongly linked to the development of stomach cancer, also known as gastric cancer. Chronic infection leads to inflammation and can result in pre-cancerous changes in the stomach lining, increasing the risk of cancer. The World Health Organization (WHO) has classified H. pylori as a Group 1 carcinogen.

What is the current treatment for H. pylori infection?

The standard treatment for H. pylori infection usually involves a combination of antibiotics and proton pump inhibitors to reduce stomach acid. However, antibiotic resistance is becoming an increasingly significant problem, making it harder to eradicate the infection.

What is an H. pylori vaccine?

An H. pylori vaccine aims to prevent infection by stimulating the immune system to recognize and combat the bacteria. Several research groups are working on developing an effective vaccine, with some candidates reaching clinical trial phases.

How could an H. pylori vaccine impact cancer rates?

A successful H. pylori vaccine could significantly reduce the incidence of stomach cancer by preventing the initial infection or reducing the chronic inflammation associated with the bacteria. This would be especially impactful in regions with high infection rates.

What are the challenges in developing an H. pylori vaccine?

Developing an H. pylori vaccine poses several challenges. The bacteria's ability to adapt and evade the immune system, the complex nature of the immune response required, and the need for the vaccine to be effective across diverse populations are significant hurdles. Additionally, the vaccine must be safe and provide long-lasting immunity.

Are there any H. pylori vaccines currently available?

As of now, there are no H. pylori vaccines available for public use. However, several candidates are in various stages of development and clinical trials, showing promise for future availability.

What is the future outlook for an H. pylori vaccine in cancer prevention?

While challenges remain, the development of an H. pylori vaccine holds great promise for significantly reducing stomach cancer rates worldwide. Continued research and clinical trials are essential to bring an effective vaccine to market, which could be a breakthrough in cancer prevention strategies.

Relevant Publications

Engineered low-pathogenic Helicobacter pylori as orally tumor immunomodulators for the stimulation of systemic immune response.

Issue Release: 2024

Chitosan-LeoA-DNA Nanoparticles Promoted the Efficacy of Novel LeoA-DNA Vaccination on Mice Against Helicobacter pylori.

Issue Release: 2024

PIRES2-EGFP/CTB-UreI vaccination activated a mixed Th1/Th2/Th17 immune system defense towards Helicobacter pylori infection in the BALB/c mice model.

Issue Release: 2024

Immunoinformatics design and synthesis of a multi-epitope vaccine against Helicobacter pylori based on lipid nanoparticles.

Issue Release: 2024

Oral Live-Carrier Vaccine of Recombinant Lactococcus lactis Inducing Prophylactic Protective Immunity Against Helicobacter pylori Infection.

Issue Release: 2024

Oral administration of DNA alginate nanovaccine induced immune-protection against Helicobacter pylori in Balb/C mice.

Issue Release: 2024

Self-assembling ferritin nanoplatform for the development of infectious hematopoietic necrosis virus vaccine.

Issue Release: 2024

[Cost-effectiveness analysis of a vaccine for Helicobacter pylori in southern Europe].

Issue Release: 2024

An M cell-targeting recombinant L. lactis vaccine against four H. pylori adhesins.

Issue Release: 2024

Recombinant L. lactis vaccine LL-plSAM-WAE targeting four virulence factors provides mucosal immunity against H. pylori infection.

Issue Release: 2024

Vaccination against Helicobacter pylori - An approach for cancer prevention?

Issue Release: 2023

Diminishing of Helicobacter pylori adhesion to Cavia porcellus gastric epithelial cells by BCG vaccine mycobacteria.

Issue Release: 2023

Mycobacterium bovis BCG increase the selected determinants of monocyte/macrophage activity, which were diminished in response to gastric pathogen Helicobacter pylori.

Issue Release: 2023

Helicobacter pylori World Gastroenterology Organization Global Guideline.

Issue Release: 2023

Designing and development of multi-epitope chimeric vaccine against Helicobacter pylori by exploring its entire immunogenic epitopes: an immunoinformatic approach.

Issue Release: 2023

Immunoinformatic prediction of potential immunodominant epitopes from cagW in order to investigate protection against Helicobacter pylori infection based on experimental consequences.

Issue Release: 2023

Estimating the prevalence of Epstein-Barr virus in primary gastric lymphoma: a systematic review and meta-analysis.

Issue Release: 2023

Baculovirus-mediated expression of a Helicobacter pylori protein-based multiepitope hybrid gene induces a potent B cell response in mice.

Issue Release: 2023

Embedding of exogenous B cell epitopes on the surface of UreB structure generates a broadly reactive antibody response against Helicobacter pylori.

Issue Release: 2023

Use of immunoinformatics and the simulation approach to identify Helicobacter pylori epitopes to design a multi-epitope subunit vaccine for B- and T-cells.

Issue Release: 2023

Why Form or Join a Cancer Team?

Are There Any Therapeutic Approaches Targeting Tryptophan Metabolism?

What Role Do Cell Culture Techniques Play?

How Can Patients Manage Stress and Anxiety?

What are Cancer Analytics?

What Are the Treatment Options for Nail Bed Cancer?

How Can Researchers and Institutions Foster Better Collaboration?

What Types of Data Are Available?

How Do Oncologists Choose Their Specialization?

How Can You Verify a Cancer Charity?

Partnered Content Networks

Relevant Topics